Suven Life Sciences
167.61
-3.69(-2.15%)
Market Cap₹3,812.70 Cr
PE Ratio-18.38
IndustryHealthcare
Company Performance:
1D-2.15%
1M-0.62%
6M-25.80%
1Y+26.24%
5Y+113.54%
View Company Insightsright
More news about Suven Life Sciences
16Jul 25
Suven Life Sciences Initiates Phase 2B Trial for Novel Depression Treatment
Suven Life Sciences has enrolled the first patient in a Phase 2B clinical trial for Ropanicant, a new drug targeting Major Depressive Disorder (MDD). This milestone marks significant progress in the company's efforts to develop innovative treatments for mental health disorders. The trial aims to evaluate the efficacy and safety of Ropanicant in a larger patient population, building on earlier promising results. This development could potentially position Suven Life Sciences as a key player in the antidepressant market and contribute valuable insights to neuropharmacology.
03Jul 25
Suven Life Sciences Allocates 29.85 Lakh Convertible Warrants to Abakkus Fund
Suven Life Sciences has allocated 29.85 lakh convertible warrants to Abakkus Diversified Alpha Fund, managed by Sunil Singhania. This allocation could potentially lead to changes in shareholding structure, capital infusion, and future equity expansion for the pharmaceutical company.
13May 25
Suven Life Sciences Secures ₹857 Crore Through Preferential Issue, Backed by Market Veterans
Suven Life Sciences has approved a preferential issue of 6.4 crore convertible warrants at ₹134 per warrant, raising up to ₹857 crore. The issue attracted investments from funds managed by market veterans Sunil Singhania and Prashant Jain. The issue price represents a 12.40% discount to the previous closing price. Following the announcement, the company's shares jumped 11.80%, reflecting positive market sentiment.
13May 25
Suven Life Sciences Issues Convertible Warrants and Reports Q4 FY24 Financial Results
Suven Life Sciences has issued 62 lakh equity convertible warrants at Rs. 134 each to two investment funds. The company's Q4 FY24 results show a 59.70% decrease in revenue to ₹2.70 crore and an increased net loss of ₹43.90 crore. For the full FY24, revenue improved by 49.09% to ₹32.80 crore, but the company still reported a net loss of ₹105.10 crore.
Suven Life Sciences
167.61
-3.69
(-2.15%)
1 Year Returns:+26.24%
Industry Peers
Syngene International
652.95
(-0.85%)
Indegene
523.35
(-1.65%)
Suven Life Sciences
167.61
(-2.15%)
Vimta Labs
619.25
(-2.60%)
Take Solutions
39.02
(+0.23%)
Bilcare
81.00
(-0.34%)
Adeshwar Meditex
16.55
(-100.00%)
Vanta Bioscience
18.72
(-9.96%)